Literature DB >> 15809206

Cytokine production by peripheral lymphocytes in melanoma.

Rafael Botella-Estrada1, Marta Escudero, José E O'Connor, Eduardo Nagore, Bernardo Fenollosa, Onofre Sanmartín, Celia Requena, Carlos Guillén.   

Abstract

BACKGROUND: The differentiation of T cells towards a T helper 1 (Th1) or Th2 phenotype based on their profile of cytokine production, is of great relevance in the regulation of immune responses. We have determined by flow cytometry, the expression of selected Th1 and Th2 cytokines by activated T cells in whole blood samples (WB) from normal donors and from patients with different clinical stages of melanoma in different clinical stages.
METHODS: WB samples from 6 normal donors and 19 patients with melanoma were activated over 4 hours with PMA + ionomycin in presence or absence of a protein secretion inhibitor. Following surface staining (CD3-Cy5+CD8-FITC), fixation and permeabilization, cells were stained with PE-labelled antibodies against Th1 cytokines (IL-2, IFN-gamma, TNF-alpha) and Th2 cytokines (IL-4, IL-10).
RESULTS: The most relevant results were related to IFN-gamma and IL-10 production. The percentage of IFN-gamma producer cells was significantly lower in melanoma patients, independent of the stage, than in controls. IL-10 production was significantly increased in melanoma patients with respect to normal donors.
CONCLUSIONS: Our data support the notion that the pattern of cytokines produced by lymphocytes from melanoma patients may help to explain the impairment in their T cell immune response. More extensive studies regarding the pattern of cytokines, not only in peripheral blood, but also in tumour tissue and sentinel lymph nodes, are needed to confirm these data.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809206

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  7 in total

1.  Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2.

Authors:  Emmanuelle Godefroy; Nina Bhardwaj
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.

Authors:  Emmanuelle Godefroy; Olivier Manches; Brigitte Dréno; Tsivia Hochman; Linda Rolnitzky; Nathalie Labarrière; Yannick Guilloux; Judith Goldberg; Francine Jotereau; Nina Bhardwaj
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

3.  Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

Authors:  Guillaume Sarrabayrouse; Christine Pich; Raphaël Moriez; Virginie Armand-Labit; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

4.  Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

Authors:  Kira Minkis; Daniel G Kavanagh; Galit Alter; Dusan Bogunovic; David O'Neill; Sylvia Adams; Anna Pavlick; Bruce D Walker; Mark A Brockman; Rajesh T Gandhi; Nina Bhardwaj
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

5.  Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.

Authors:  Rebecca J Critchley-Thorne; Ning Yan; Serban Nacu; Jeffrey Weber; Susan P Holmes; Peter P Lee
Journal:  PLoS Med       Date:  2007-05       Impact factor: 11.069

Review 6.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17

7.  Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.

Authors:  E Verronèse; A Delgado; J Valladeau-Guilemond; G Garin; S Guillemaut; O Tredan; I Ray-Coquard; T Bachelot; A N'Kodia; C Bardin-Dit-Courageot; C Rigal; D Pérol; C Caux; C Ménétrier-Caux
Journal:  Oncoimmunology       Date:  2015-11-10       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.